Seegene expects to keep up sales hot streak on global test kit demand
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
“Monthly sales that averaged 100 billion won ($84 million) until September last year picked up to double the average in December,” said Kim Bum-Joon, the Chief Management Officer at Seegene in an recent interview with Maeil Business Newspaper.
Seegene achieved sales milestone of 1.1 trillion won in 2020, the first year of pandemic. It estimates stronger growth last year and for this year.
“There had been doubts about Seegene in the pandemic wake. But given the ‘living with Covid-19’ environment around the world, demand for test kits is expected to go on,” he said.
Currently, about 90% of Seegene's annual sales are generated from overseas, with the bulk coming from Europe. On Dec. 19, 2.8 million diagnostic reagents were airlifted on a chartered flight to five European countries and on Dec. 29, 1.7 million were sent to Israel.
The company this year expects a boon from the United States, where the federal government is handing out 500 million test kits for free to tackle record surge in infections.
Seegene entered a partnership agreement in July last year with U.S. biotechnology company Bio-Rad Laboratories for clinical development and commercialization of infectious disease molecular diagnostic products.
Despite high barriers for foreign companies because of the competition and the tendency for U.S. government to prioritize its domestic companies, Seegene’s test equipment gained FDA approval without going through a separate product development process through the partnership with Bio-Rad.
Seegene has received approval of its Allplex SARS-CoV-2/FluA/FluB/RSV Assay in Canada on Jan. 11 and hopes for a nod from U.S. authorities. Allplex SARS-CoV-2/FluA/FluB/RSV Assay is a multiplex real-time PCR assay that can distinguish from flu to Covid-19 symptoms in a single test which can be more accurate in diagnosis.
Seegene has been ratcheting up marketing pitch. Its YouTube video titled “Seegene Vision Film, A Better Future With Molecular Diagnostics”, created by Seegene CEO Chun Jong-yoon, drew 110 million views as of Jan. 2.
Shares of Kosdaq-tradign Seegene are 1 percent higher at 54,700 won as of 12:45 p.m. Tuesday.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- KSOE remains on track to achieve annual target despite M&A setback - Pulse by Maeil Business News Korea
- CrystalGenomics and GemVax advance clinical test for pancreatic and Alzheimer’s illness - Pulse by Maeil Business News Korea
- Iljin Materials to invest $555 mn in Malaysian subsidiary to up elecfoil output - Pulse by Maeil Business News Korea
- Hyundai, Kia, Genesis connected car service brands to be integrated into one - Pulse by Maeil Business News Korea
- Louis Vuitton mulls shuttering downtown duty-free shops in S. Korea - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- AI가 실시간으로 가격도 바꾼다…아마존·우버 성공 뒤엔 ‘다이내믹 프라이싱’
- 서예지, 12월 29일 데뷔 11년 만에 첫 단독 팬미팅 개최 [공식] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이